From The
Stage

Expert perspectives focused on the latest bioanalytical topic & trends

Key Takeaways from the 14th Annual PEGS Summit

Our team recently attended the 14th Annual PEGS Summit to participate in discussions around advancements in biotherapeutic protein drug development and how they impact the work we do with large molecule biologics. From improving efficacy of CAR-T cell therapies to managing the challenges of immunogenicity testing, we’ve summarized the most compelling insights we gained at this year’s event.

Read More »
Evaluation of CAR T-Cell Therapy Toxicities

Evaluation of CAR T-Cell Therapy Toxicities by Measurement of Cytokines During Therapy

T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). CAR-T cells have demonstrated clinical efficacy in hematologic malignancies and targeting solid tumors. However, CAR-T therapy also can elicit cytokine release syndrome (CRS) cytotoxicity. This unwanted release of cytokines has also been seen following the infusion of therapeutic monoclonal antibodies (mAbs), systemic interleukin-2 (IL-2), and the bispecific CD19-CD3 T-cell engaging antibody blinatumomab.

Read More »

Key Takeaways from the 12th Workshop on Recent Issues in Bioanalysis (WRIB)

Scientists from BioAgilytix recently attended the 12th WRIB in Philadelphia, PA. Meeting new contacts in the industry and taking part in discussions concerning the most innovative topics in bioanalysis, biomarkers, and immunogenicity was a genuinely valuable and enjoyable experience. We recap the topics that our team found to be most interesting at WRIB this year.

Read More »

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.